(PCVX) - Analyzing Vaxcyte's Short Interest
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
Alexandria Real Estate Equities, Inc. Announces Long-Term 258,581 RSF Lease With Longstanding Tenant Vaxcyte, Inc. at the Alexandria Center for Life Science - San Carlos Mega Campus
Vaxcyte Insider Sold Shares Worth $686,518, According to a Recent SEC Filing
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
US MOVERS&SHAKERS Nov 11-Nov 15, 2024
"Anti-vaccine pioneer" nominated by Trump as Secretary of Health, vaccine stocks plummeted.
Trump nominated Robert F. Kennedy Jr. to be the Secretary of Health. Kennedy holds many unorthodox views in the field of public health, the most famous of which is questioning the safety and effectiveness of vaccines. He referred to vaccine injections as "crimes against humanity" during the COVID-19 pandemic and likened it to the Nazi Holocaust.
Vaccine-maker Stocks Like Moderna, Pfizer Drop as Trump Picks RFK Jr. to Lead HHS
Vaxcyte Gets FDA Breakthrough Therapy Designation for Its Pneumococcal Disease Treatment
Express News | Vaxcyte Announces FDA Clearance for VAX-31 Infant Phase 2 Study and Breakthrough Therapy Designation for Adult Phase 3 Study
Express News | Vaxcyte Inc: Expects to Initiate Vax-31 Infant Phase 2 Study by End of January 2025
Express News | Vaxcyte Inc: Vax-31 Infant Indication: Investigational New Drug Application Cleared by FDA
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Express News | Vaxcyte Provides Positive Regulatory Updates on Vax-31 Pediatric and Adult Programs
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
Express News | Cantor Fitzgerald Reiterates Overweight on Vaxcyte
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $135
BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $160